rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    COGT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cogent: A Promising Technology, But Valuation Leaves No Room For Error

      Cogent Biosciences (COGT) stock is a hold, as bezuclastinib's 16.5-month GIST PFS is offset by shares near $29 versus $29.83 fair value.

      19h agoSeeking AlphaCOGT
      Cogent Biosciences (COGT) Stock Looks Fully Priced Against Its Asset Base
      Nov 18Yahoo FinanceCOGT
      Cogent Biosciences at Jefferies: launch plans hinge on bezuclastinib
      Nov 17Investing.comCOGTJEF
      Cogent Biosciences at UBS conference: three approvals in sight
      Nov 17Investing.comCOGTUBS
      Cogent Biosciences stock hits 52-week low at 27.73 USD
      Nov 16Investing.comCOGT
      Cogent Biosciences at Guggenheim conference: launch nears
      Nov 10Investing.comCOGT
      Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
      Nov 5Yahoo FinanceCOGT
      Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Merck & Company (MRK) and Alnylam Pharma (ALNY)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailALNYCOGT
      Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
      Oct 27Yahoo FinanceCOGT
      If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
      Oct 21BenzingaCOGT
      Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
      Oct 20Yahoo FinanceCOGT
      Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years - Cogent Bioscien

      Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 14.59% on an annualized basis producing an average annual return of 26.37%. Currently, Cogent Biosciences has a market capitalization

      Oct 12BenzingaCOGT
      Guggenheim Remains a Buy on Cogent Biosciences (COGT)

      Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailCOGT
      $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Cogent Biosciences (NAS

      Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalization

      Oct 2BenzingaCOGT
      Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA

      Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s valuation stacks up against the company’s book value. Over the past 5 years the stock is up about 2.7x. This puts real pressure on the question of whether the current price is still in line with what its...

      Sep 25Yahoo FinanceCOGT
      Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

      Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased recently, with the 30 day share price return down 13.3% and the 90 day share price return down 17.4%. However, the 1 year total shareholder return of 137.1% suggests earlier optimism around its broader...

      Sep 24Yahoo FinanceCOGT
      Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?

      Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal APEX trial data showing clinically meaningful responses and durable clinical activity in Advanced Systemic Mastocytosis, while parallel NDA reviews in NonAdvanced SM and GIST point to a broader...

      Sep 24Yahoo FinanceCOGT
      Cogent Biosciences: A Closer Look At Bezuclastinib And Its Long-Term Potential (NASDAQ:COGT)
      Sep 23Seeking AlphaCOGT
      Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
      Sep 17BenzingaCOGT
      Analysts Are Bullish on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Thermo Fisher (TMO)

      Detailed price information for Thermo Fisher Scientific (TMO-N) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailCOGTMRVI
      Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ)
      Sep 15Seeking AlphaCOGT
      Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

      NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accep

      Sep 15Yahoo FinanceCOGT
      Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application
      Sep 15Yahoo FinanceCOGT
      Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
      Sep 2Yahoo FinanceCOGT
      $100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
      Aug 31BenzingaCOGT
      Cogent Biosciences director Arlene Morris sells $1.69m shares
      Aug 31Investing.comCOGT
      Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing

      Arlene Morris, Director, on August 27, 2026, sold 45,510 shares in Cogent Biosciences (COGT) for $1,

      Aug 31Yahoo FinanceCOGT
      Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

      Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS...

      Aug 28BarchartCOGT
      Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT)

      Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Learn more about COGT stock here.

      Aug 27Seeking AlphaCOGT

      This is the newest page. Registered accounts read further back.